As it is known that PSGL-1 binds versican, and that versican seems to be playing a pro-tumoral role in the TME, it is possible that versican-PSGL-1 interactions in the tumor microenvironment may inhibit T cell infiltration and prevent tumor killing (Figure 2). Here, VCAN is linked to neoplasm.